Radiosensitization of brain metastasis by targeting c-MET

Laboratory Investigation

Volumn 93, Issue 3, 2013, Pages 344-353

  Yang, Heekyoung ^a   Lee, Hye Won ^a   Kim, Yonghyun ^b   Lee, Yeri ^a   Choi, Yeon Sook ^a   Kim, Kang Ho ^a   Jin, Juyoun ^a   Lee, Jeongwu ^c   Joo, Kyeung Min ^a,d   Nam, Do Hyun ^a  

^a Samsung Medical Center   (South Korea)

^b UNIVERSITY OF ALABAMA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

breast cancer brain metastasis; c Met; radioresistance

Indexed keywords

CRIZOTINIB; RETROVIRUS VECTOR; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IRRADIATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION INDUCED NEOPLASM; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

EID: 84874585254     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.180     Document Type: Article

References (53)

1. Arslan C, Dizdar O, Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother 2010;11: 1089-1100
2. Altundag K, Bondy ML, Mirza NQ, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007;110: 2640-2647
3. Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803
4. Shaffrey ME, Mut M, Asher AL, et al. Brain metastases. Curr Probl Surg 2004;41:665-741
5. Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007;60: 277-283, discussion 283-274
6. Palmieri D, Fitzgerald D, Shreeve SM, et al. Analyses of resected human brain metastases of breast cancer reveal the association between upregulation of hexokinase 2 and poor prognosis. Mol Cancer Res 2009;7:1438-1445
7. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 2009;10:1037-1044
8. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010;77:655-661
9. Acosta-Jamett G, Astorga-Arancibia F, Cunningham AA. Comparison of chemical immobilization methods in wild foxes (Pseudalopex griseus and Pseudalopex culpaeus) in Chile. J Wildl Dis 2010;46: 1204-1213
10. Debeb BG, Xu W, Woodward WA. Radiation resistance of breast cancer stem cells: Understanding the clinical framework. J Mammary Gland Biol Neoplasia 2009;14:11-17
11. Glynne-Jones R, Sebag-Montefiore D. Chemoradiation schedules-what radiotherapy? Eur J Cancer 2002;38:258-69
12. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-2106
13. Gebski V, Lagleva M, Keech A, et al. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: A clinical perspective. J Natl Cancer Inst 2006;98:26-38
14. Jenkinson MD, Haylock B, Shenoy A, et al. Management of cerebral metastasis: Evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011;47:649-655
15. Ricard D, Taillia H, Renard JL. Brain damage from anticancer treatments in adults. Curr Opin Oncol 2009;21:559-565
16. Zhu Y, Hu J, Hu Y, et al. Targeting DNA repair pathways: A novel approach to reduce cancer therapeutic resistance. Cancer Treat Rev 2009; 35:590-596
17. Palena C, Fernando RI, Litzinger MT, et al. Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Exp Biol Med (Maywood) 2011;236: 537-545
18. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760
19. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/ CD44 breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-1785
20. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009;106:13820-13825
21. Woodward WA, Chen MS, Behbod F, et al. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007;104:618-623
22. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768
23. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988
24. Vande Woude GF, Jeffers M, Cortner J, et al. Met-HGF/SF: Tumorigenesis, invasion and metastasis. Ciba Found Symp 1997;212:119-130, discussion 130-112, 148-154
25. Joo KM, Jin J, Kim E, et al. MET Signaling Regulates Glioblastoma Stem Cells. Cancer Res 2012;72:3828-3838
26. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011;103:645-661
27. Qian LW, Mizumoto K, Inadome N, et al. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer 2003;104:542-549
28. Franken NA, Rodermond HM, Stap J, et al. Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-2319
29. Price JE, Polyzos A, Zhang RD, et al. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990;50:717-721
30. Price JE, Zhang RD. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev 1990;8:285-297
31. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of shortversus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798-804
32. Rades D, Huttenlocher S, Dunst J, et al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol 2010;28:3597-3604
33. Gril B, Evans L, Palmieri D, et al. Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer 2010;46:1204-1210
34. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204
35. Liu SK, Olive PL, Bristow RG. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev 2008;27:445-458
36. Ahmed KM, Li JJ. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 2008;44:1-13
37. Szumiel I. Epidermal growth factor receptor and DNA double strand break repair: The cell's self-defence. Cell Signal 2006;18:1537-1548
38. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNAdependent protein kinase. J Biol Chem 2005;280:31182-31189
39. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in nodepositive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-682
40. Ghoussoub RA, Dillon DA, D'Aquila T, et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998;82:1513-1520
41. Medova Michaela, Aebersold DM, Blank-Liss Wieslawa, et al. MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-damaging agents potentially by breaching a damageinduced checkpoint arrest. Genes Cancer 2011;1:1053-1062
42. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925
43. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-516
44. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-2214
45. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18:87-96
46. Nakamura T, Matsumoto K, Kiritoshi A, et al. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Res 1997;57:3305-313
47. Rong S, Bodescot M, Blair D, et al. Tumorigenicity of the met protooncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992;12:5152-5158
48. Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010;70:6880-6890
49. Joo KyeungMin, Jin J, Kim Eunhee, et al. MET signaling regulates glioblastoma stem cells. Cancer Res 2012;72:3828-3838
50. Suzuki A, Nakauchi H, Taniguchi H. Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. Diabetes 2004;53:2143-2152
51. Boccaccio C, Comoglio PM. Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-645
52. Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 2010;10:375-379
53. Gillet JP, Calcagno AM, Varma S, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anticancer drug resistance. Proc Natl Acad Sci USA 2011;108:18708-18713